Revenues for the first half of 2023 and update on AB Science’s activities
29/09/2023 – AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18/09/2023 – AB Science today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS)
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
26/06/2023 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
01/06/2023 – AB Science today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023
30/05/2023 – AB Science will hold its Annual General Meeting on Friday 30 June 2023 at 3.30pm
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
Annual financial results as of 31 December, 2022
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
Presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting